VIATRIS INC

NASDAQ: VTRS (Viatris Inc.)

Last update: 08 Jun, 6:31AM

10.47

0.05 (0.48%)

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Bullish Bullish
Drug Manufacturers - Specialty & Generic (Global) Bullish Bullish
Stock Viatris Inc. Bullish Bearish

Stockmoo Consensus

Strong Sell
Sell
Neutral
Buy
Strong Buy

Similar Stocks

Stock Market Cap DY P/E P/B
VTRS 12 B 4.59% - 0.610
NBIX 14 B - 37.36 5.67
HCM 3 B - 29.68 4.19
LNTH 5 B - 12.06 5.80
AVDL 2 B - - 18.40
CRON 882 M - - 0.830

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Mid Value

Ownership

Name Date Shares Held
Davis Selected Advisers 31 Mar 2024 57,465,399
52 Weeks Range
8.74 (-16%) — 13.62 (30%)
Median 13.00 (24.16%)
Total 1 Hold
Firm Date Target Price Call Price @ Call
Piper Sandler 28 Mar 2024 13.00 (24.16%) Hold 11.94
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
MALIK RAJIV - 10.28 -349,960 -3,577,938
Aggregate Net Quantity -349,960
Aggregate Net Value ($) -3,577,938
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 10.28
Name Holder Date Type Quantity Price Value ($)
MALIK RAJIV Director 14 Jun 2024 Sell (-) 264,300 10.17 2,687,931
MALIK RAJIV Director 13 Jun 2024 Sell (-) 85,660 10.39 890,007
Date Type Details
07 Jun 2024 Announcement Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024
04 Jun 2024 Announcement Viatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
03 Jun 2024 Announcement Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors
31 May 2024 Announcement Viatris to Participate in the Jeffries Global Healthcare Conference
21 May 2024 Announcement Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale
09 May 2024 Announcement Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
02 May 2024 Announcement Viatris to Participate in the BofA Securities 2024 Health Care Conference
01 May 2024 Announcement Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
16 Apr 2024 Announcement Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
15 Apr 2024 Announcement Viatris Appoints Corinne Le Goff as Chief Commercial Officer
01 Apr 2024 Announcement Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
01 Apr 2024 Announcement Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States
27 Mar 2024 Announcement Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
Show more
TTM Dividend Yield 4.59%
3Y Average Dividend Yield 3.73%
Expected Next Dividend Payment Sep 2024
Ex Date Announcement Date Payment Date Details
23 May 2024 06 May 2024 14 Jun 2024 0.12 Cash
08 Mar 2024 26 Feb 2024 18 Mar 2024 0.12 Cash
22 Nov 2023 06 Nov 2023 15 Dec 2023 0.12 Cash
23 Aug 2023 04 Aug 2023 15 Sep 2023 0.12 Cash
23 May 2023 05 May 2023 16 Jun 2023 0.12 Cash
08 Mar 2023 24 Feb 2023 17 Mar 2023 0.12 Cash
22 Nov 2022 03 Nov 2022 16 Dec 2022 0.12 Cash
23 Aug 2022 04 Aug 2022 16 Sep 2022 0.12 Cash
23 May 2022 05 May 2022 16 Jun 2022 0.12 Cash
23 Feb 2022 04 Jan 2022 16 Mar 2022 0.12 Cash
22 Nov 2021 05 Nov 2021 16 Dec 2021 0.11 Cash
23 Aug 2021 06 Aug 2021 16 Sep 2021 0.11 Cash
21 May 2021 07 May 2021 16 Jun 2021 0.11 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 0.240 2 2.29
2023 0.480 4 4.43
2022 0.480 4 4.31
2021 0.330 3 2.44

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No data